Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Other Operating Expenses (2024 - 2025)

Silence Therapeutics' Other Operating Expenses history spans 2 years, with the latest figure at -$20.7 million for Q2 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$20.7 million in Q2 2025 year-over-year; TTM through Dec 2025 was -$42.9 million, a 160.98% decrease, with the full-year FY2024 number at -$113.6 million, changed N/A from a year prior.
  • Other Operating Expenses hit -$20.7 million in Q2 2025 for Silence Therapeutics, up from -$22.2 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for SLN hit a ceiling of -$16.5 million in Q1 2024 and a floor of -$22.2 million in Q1 2025.